Search results for "Nucleoside"

showing 10 items of 166 documents

Changes in protein domains outside the catalytic site of the bacteriophage Qβ replicase reduce the mutagenic effect of 5-azacytidine.

2014

ABSTRACT The high genetic heterogeneity and great adaptability of RNA viruses are ultimately caused by the low replication fidelity of their polymerases. However, single amino acid substitutions that modify replication fidelity can evolve in response to mutagenic treatments with nucleoside analogues. Here, we investigated how two independent mutants of the bacteriophage Qβ replicase (Thr210Ala and Tyr410His) reduce sensitivity to the nucleoside analogue 5-azacytidine (AZC). Despite being located outside the catalytic site, both mutants reduced the mutation frequency in the presence of the drug. However, they did not modify the type of AZC-induced substitutions, which was mediated mainly by …

Mutation rateImmunologyMutantRNA-dependent RNA polymeraseBiologyVirus ReplicationMicrobiologyViral ProteinsVirologyCatalytic DomainmedicineGeneticsAllolevivirusNucleoside analogueQ beta Replicasebiology.organism_classification3. Good healthProtein Structure TertiaryViral replicationBiochemistryAmino Acid SubstitutionGenetic Diversity and EvolutionInsect ScienceAzacitidineQ beta ReplicaseBacteriophage QβNucleosidemedicine.drugMutagensJournal of virology
researchProduct

2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.

2004

Several 1,3-thiazolidin-4-ones bearing a 2,6-dihalophenyl group at C-2 and a substituted pyrimidin-2-yl ring at the N-3 were synthesised and evaluated as anti-HIV agents. The results of the in vitro tests showed that some of them were highly effective inhibitors of human immunodeficiency virus type-1 (HIV-1) replication at 10–40 nM concentrations with minimal cytotoxicity. Structure–activity relationship studies revealed that the nature of the substituents at the 2 and 3 positions of the thiazolidinone nucleus had a significant impact on the in vitro anti-HIV activity of this class of potent antiretroviral agents. The compounds had significantly reduced activity against the characteristic N…

NNRTI3-Thiazolidin-4-onesAnti-HIV activity13-Thiazolidin-4-oneNNRTIs; 1; 3-Thiazolidin-4-ones; anti-HIVAnti-HIV Agents1Drug Evaluation PreclinicalMutation MissenseBiologyVirus ReplicationVirusStructure-Activity RelationshipVirologyDrug Resistance ViralmedicineStructure–activity relationshipCytotoxicityPharmacologyReverse-transcriptase inhibitorMolecular Structurevirus diseasesanti-HIVSettore CHIM/08 - Chimica FarmaceuticaMolecular biologyIn vitroReverse transcriptaseThiazolesPyrimidinesViral replicationAmino Acid SubstitutionNNRTIsHIV-1Reverse Transcriptase InhibitorsNucleosidemedicine.drugAntiviral research
researchProduct

Investigating the Role of Guanosine on Human Neuroblastoma Cell Differentiation and the Underlying Molecular Mechanisms

2021

Neuroblastoma arises from neural crest cell precursors failing to complete the process of differentiation. Thus, agents helping tumor cells to differentiate into normal cells can represent a valid therapeutic strategy. Here, we evaluated whether guanosine (GUO), a natural purine nucleoside, which is able to induce differentiation of many cell types, may cause the differentiation of human neuroblastoma SH-SY5Y cells and the molecular mechanisms involved. We found that GUO, added to the cell culture medium, promoted neuron-like cell differentiation in a time- and concentration-dependent manner. This effect was mainly due to an extracellular GUO action since nucleoside transporter inhibitors r…

NeuriteCellular differentiationGuanosinePurine nucleoside phosphorylaseRM1-950Nucleoside transporterSettore BIO/09 - Fisiologiachemistry.chemical_compoundneuroblastomaguanine guanosine guanylate cyclase heme oxygenase neuroblastoma protein kinase C purine nucleoside phosphorylase SH-SY5YdifferentiationNucleòsidsExtracellularPharmacology (medical)guaninePharmacologybiologyMarcadors tumoralsNucleosidesSH-SY5YdifferentiationBrief Research Reportheme oxygenasepurine nucleoside phosphorylaseCell biologyguanylate cyclaseguanosinechemistryCell cultureTumor markersSettore BIO/14 - Farmacologiabiology.proteinTherapeutics. PharmacologyNucleosideprotein kinase C
researchProduct

Nucleoside phosphotransferase in animal tissues

1984

Nucleoside phosphotransferase
researchProduct

DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective stu…

2002

Purpose: The aim of this study was to determine TP53 and NM23-H1 immunoreactivity, DNA ploidy, and S-phase fraction (SPF) in a series of 160 patients undergoing resective surgery for primary operable colorectal cancer (CRC) and to establish whether these alterations have any clinical value in predicting CRC patients' prognosis. Methods: TP53 and NM23-H1 expressions were evaluated on paraffin-embedded tissue by immunohistochemistry and DNA-ploidy and SPF on frozen tissue by flow-cytometric analysis. Results: The median follow-up time in our study group was 71 months (range 34-115 months). P53 protein expression was associated with distal tumors (P < 0.05) and DNA aneuploid tumors (P < …

OncologyCancer Researchmedicine.medical_specialtyPathologyFlow-cytometric variableTime FactorsTumor suppressor geneColorectal cancerPrognosiSettore MED/06 - Oncologia MedicaColonRectumBiologyAdenocarcinomaDisease-Free SurvivalS PhasePredictive Value of TestsInternal medicinemedicineBiomarkers TumorHumansStage (cooking)Prospective cohort studyMonomeric GTP-Binding ProteinsNeoplasm StagingTP53 expressionHematologyPloidiesGeneral MedicineDNA NeoplasmCell cycleNM23 Nucleoside Diphosphate Kinasesmedicine.diseaseColorectal cancerAdenocarcinoma MucinousImmunohistochemistrySurvival Analysismedicine.anatomical_structureTreatment OutcomeOncologyNucleoside-Diphosphate KinaseImmunohistochemistryLymph NodesTumor Suppressor Protein p53Colorectal NeoplasmsCell DivisionTranscription FactorsJournal of cancer research and clinical oncology
researchProduct

Nm-23-H1 expression does not predict clinical survival in colorectal cancer patients

2003

The gene Nm23, which encodes for a nucleoside diphosphate kinase, has been defined as a metastasis-suppressor gene because of the inverse correlation between its expression and the metastatic capacity of the tumor cells. For colorectal cancer, however, the findings are equivocal. The aim of our study was to assess, in 160 patients undergoing surgery for colorectal cancer (CRC), the expression of the Nm23-H1 protein and to evaluate its possible associations with traditional clinicopathologic variables, with DNA-ploidy and proliferative activity (S-phase fraction, SPF), and with disease-free and overall survival of patients. Nm23-H1 expressions were evaluated on paraffin-embedded tissue by im…

OncologyCytoplasmCancer Researchmedicine.medical_specialtyPathologyTime FactorsSettore MED/06 - Oncologia MedicaColorectal cancerBiologyDisease-Free SurvivalS PhaseInternal medicineNm23-H1 expressionmedicineHumansClinical significancePloidiesModels GeneticOncogeneCancerExonsGeneral MedicineNM23 Nucleoside Diphosphate KinasesCell cycleFlow CytometryPrognosismedicine.diseaseImmunohistochemistryColorectal cancerMolecular medicineOncologyTumor progressionNucleoside-Diphosphate KinaseProtein BiosynthesisDisease ProgressionImmunohistochemistryColorectal NeoplasmsCell Division
researchProduct

Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer.

2010

Nucleoside transporter proteins are specialized proteins that mediate the transport of nucleosides and nucleoside analog drugs across the plasma membrane. The human equilibrative nucleoside transporter 1 (hENT1) is a member of these proteins and mediates cellular entry of gemcitabine, cytarabine, and fludarabine. The hENT1 expression has been demonstrated to be related with prognosis and activity of gemcitabine-based therapy in breast, ampullary, lung, and pancreatic cancer. We investigated the immunohistochemical expression of hENT in tumor samples from 111 patients with resected gastric adenocarcinoma, correlating these data with clinical parameters and disease outcomes. None of the patie…

OncologyMaleSettore MED/06 - Oncologia MedicaPhysiologymedicine.medical_treatmentClinical BiochemistryNucleoside transporterEquilibrative nucleoside transporter 1Cohort StudiesMedicineNeoplasm MetastasisAged 80 and overbiologyMiddle AgedPrognosisImmunohistochemistryFludarabineSurvival RateDisease ProgressionFemalemedicine.drugAdultmedicine.medical_specialtyNucleoside transporterAntineoplastic AgentsAdenocarcinomaDisease-Free SurvivalEquilibrative Nucleoside Transporter 1Predictive Value of TestsStomach NeoplasmsPancreatic cancerInternal medicineBiomarkers TumorHumansSurvival rateAgedRetrospective Studiesbusiness.industryCancerCell Biologymedicine.diseaseGemcitabineRadiation therapyDrug Resistance NeoplasmGastric MucosaImmunologybiology.proteinNeoplasm Recurrence LocalbusinessJournal of cellular physiology
researchProduct

Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study

2011

Abstract Background and purpose Fludarabine is an adenine nucleoside analogue that has significant activity in hematological malignancies and has shown promising activity in combination with radiation in preclinical solid tumor models. We designed a phase I trial exploring concurrent fludarabine and radiotherapy in patients with advanced non-small cell lung cancer (NSCLC) to determine the maximum tolerated dose (MTD) of fludarabine given with concurrent irradiation. Materials and methods Thirteen patients with stage IIIB NSCLC received thoracic irradiation of 60 Gy. Fludarabine was administered during the 5th and 6th week of radiotherapy. Doses started at 10 mg/m2 per day and increased by s…

Oncologymedicine.medical_specialtyCancer ResearchRadiation-Sensitizing AgentsLung Neoplasmsmedicine.medical_treatmentAntineoplastic AgentsNSCLCMedicine & Public Health; Hematology; Oncology; Internal Medicine; Cancer Research03 medical and health sciencesFludarabine0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungCarcinomaMedicineCombined Modality TherapyHumansConcurrent fludarabine and radiotherapy030304 developmental biologyNeoplasm Staging0303 health sciencesOriginal PaperHematologyNucleoside analoguebusiness.industryRadiotherapy DosageGeneral MedicineAdenine nucleosideRadiochemotherapy in stage III NSCLC locally advanced inoperable NSCLCNucleoside analoguemedicine.diseaseCombined Modality Therapy3. Good healthFludarabinerespiratory tract diseasesClinical trialRadiation therapyOncology030220 oncology & carcinogenesisRadiotherapy phase I studybusinessFludarabine; NSCLC; Nucleoside analogue; Concurrent fludarabine and radiotherapy; Radiotherapy phase I study; Radiochemotherapy in stage III NSCLC locally advanced inoperable NSCLCVidarabinemedicine.drug
researchProduct

Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC)

2009

Background and aim: Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patients' outcome according to the expression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy. Materials and Methods: The immunohistochemistry analysis was performed on samples from thirty-one patients with unresectable biliary tract cancer (BTC) consecutively treated with first line gemcitabine-based regimens. Results: Positive hENT1 staining patients were…

Oncologymedicine.medical_specialtyPathologyCancer ResearchAntimetabolites Antineoplasticmedicine.medical_treatmentEquilibrative nucleoside transporter 1DeoxycytidineEquilibrative Nucleoside Transporter 1Statistical significanceInternal medicineDrug DiscoveryMedicineHumansHENT1PharmacologyChemotherapyUnivariate analysisPredictive markerBiliary tract cancer; Gemcitabine; HENT1; Predictive factor; Drug Discovery3003 Pharmaceutical Science; Pharmacology; Cancer Researchbiologybusiness.industryDrug Discovery3003 Pharmaceutical ScienceCancermedicine.diseaseImmunohistochemistryGemcitabineGemcitabineBiliary Tract NeoplasmsOncologybiology.proteinImmunohistochemistryBiliary tract cancerbusinessPredictive factormedicine.drug
researchProduct

Differential Effects of Tenofovir/Emtricitabine and Abacavir/Lamivudine on Human Leukocyte Recruitment

2012

Background The association of abacavir (ABC) with cardiovascular disease has led to HIV treatment guidelines favouring the combination of tenofovir/emtricitabine (TDF/FTC) over that of ABC/lamivudine (ABC/3TC). We have analysed the effects of plasma-relevant concentrations of TDF, FTC, ABC and 3TC, individually and in clinically employed combinations, on human leukocyte accumulation. The effects of ABC, 3TC, TDF and FTC on the expression of adhesion molecules were also evaluated. Methods Interactions between human leukocytes – specifically peripheral blood polymorphonuclear or mono-nuclear cells – and human umbilical vein endothelial cells were evaluated in a flow chamber reproducing in viv…

OrganophosphonatesHIV InfectionsCD18Cell CommunicationPharmacologyEmtricitabineDeoxycytidinePeripheral blood mononuclear cellIn vivoAbacavirAntiretroviral Therapy Highly ActiveCell AdhesionLeukocytesmedicineEmtricitabineHumansPharmacology (medical)TenofovirPharmacologyCell adhesion moleculebusiness.industryAdenineEndothelial CellsLamivudineAbacavir/LamivudineDideoxynucleosidesDrug CombinationsInfectious DiseasesLamivudinebusinessCell Adhesion Moleculesmedicine.drugAntiviral Therapy
researchProduct